Advanced Neoplasm Clinical Trial
Official title:
Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b for Antiangiogenic/Antivascular Effect in Adult Advanced Neoplasm
Purpose:
This phase I trial estimates the antiangiogenic and antivascular effect of 4 different
levels of continuous low doses of the combination of Vinorelbine, Cyclophosphamide and
Interferon alpha 2b (" metronomic chemotherapy ")in adult advanced neoplasm.
This study is non randomized, monocentric, and with a pharmacodynamic part.
Primary objective:
Estimation of the toxicity of the combination of continuous low doses of Vinorelbine,
Cyclophosphamide and Interferon alpha 2b.
Secondary objectives:
Estimation of the antiangiogenic and/or antivascular effect (VEGF measurement) in
radiography (DEC-MRI), biology and immunohistochemistry of the treatment.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment